JP2021511352A5 - - Google Patents
Info
- Publication number
- JP2021511352A5 JP2021511352A5 JP2020540571A JP2020540571A JP2021511352A5 JP 2021511352 A5 JP2021511352 A5 JP 2021511352A5 JP 2020540571 A JP2020540571 A JP 2020540571A JP 2020540571 A JP2020540571 A JP 2020540571A JP 2021511352 A5 JP2021511352 A5 JP 2021511352A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrate
- pharmaceutically acceptable
- acceptable salt
- bet inhibitor
- volasertib
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18153471 | 2018-01-25 | ||
| EP18153471.0 | 2018-01-25 | ||
| PCT/EP2019/051733 WO2019145410A1 (en) | 2018-01-25 | 2019-01-24 | Combination treatment of acute myeloid leukemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021511352A JP2021511352A (ja) | 2021-05-06 |
| JP2021511352A5 true JP2021511352A5 (https=) | 2022-02-01 |
| JPWO2019145410A5 JPWO2019145410A5 (https=) | 2022-02-01 |
Family
ID=61198661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540571A Pending JP2021511352A (ja) | 2018-01-25 | 2019-01-24 | 急性骨髄性白血病の併用処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210038602A1 (https=) |
| EP (1) | EP3743067A1 (https=) |
| JP (1) | JP2021511352A (https=) |
| CN (1) | CN111629725A (https=) |
| WO (1) | WO2019145410A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220356525A1 (en) * | 2019-10-16 | 2022-11-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether patients suffering from acute myeloid leukemia will achieve a response to an myc-targeting therapy |
| WO2022184664A1 (en) | 2021-03-02 | 2022-09-09 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0318145A (pt) | 2003-02-26 | 2006-02-21 | Boehringer Ingelheim Pharma | dihidropteridinonas, processos para a sua preparação e sua aplicação como medicamento |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
| CN104968334B (zh) * | 2012-09-28 | 2018-09-14 | 翁科埃斯克斯有限公司 | 包含噻吩并三唑并二氮杂卓化合物的药物制剂 |
| US9422290B2 (en) | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
| US9266891B2 (en) * | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
| JP2016525531A (ja) * | 2013-07-26 | 2016-08-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 急性骨髄性白血病及び骨髄異形成症候群の処置のためのアザシチジンと組み合わせたボラセルチブ |
| US20150051208A1 (en) * | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
| US9428513B2 (en) * | 2013-11-07 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
| US9428515B2 (en) * | 2014-05-09 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Benzimidazole derivatives |
| WO2016044694A1 (en) * | 2014-09-19 | 2016-03-24 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
-
2019
- 2019-01-24 CN CN201980009504.0A patent/CN111629725A/zh active Pending
- 2019-01-24 EP EP19700964.0A patent/EP3743067A1/en not_active Withdrawn
- 2019-01-24 JP JP2020540571A patent/JP2021511352A/ja active Pending
- 2019-01-24 WO PCT/EP2019/051733 patent/WO2019145410A1/en not_active Ceased
- 2019-01-24 US US16/964,023 patent/US20210038602A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024133474A5 (https=) | ||
| JP2016518387A5 (https=) | ||
| JP2014526503A5 (https=) | ||
| JP2014515373A5 (https=) | ||
| JP2006504795A5 (https=) | ||
| JP2015526458A5 (https=) | ||
| JP2015505564A5 (https=) | ||
| JP2019517542A5 (https=) | ||
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| JP2019515909A5 (https=) | ||
| JP2012193216A5 (https=) | ||
| JP2019517587A5 (https=) | ||
| JP2020521797A5 (https=) | ||
| JP2021529829A5 (https=) | ||
| WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
| JP2021535147A5 (https=) | ||
| JP2018138596A5 (https=) | ||
| JP2021530543A5 (https=) | ||
| JPWO2019241442A5 (https=) | ||
| JP2021511352A5 (https=) | ||
| JP2021522246A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| JP2014534229A5 (https=) | ||
| JP2019507786A5 (https=) |